LB Pharmaceuticals Inc income statement LBRX

It recorded a net loss of $59.1 million. Diluted earnings per share were -$1.79.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the same quarter a year earlier.

Line
TTM
Sep 30, 2026
Q3 FY2026
Sep 30, 2026
Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Q4 FY2025
Dec 31, 2025
Q3 FY2025
Sep 30, 2025
Research and development
119
52
+2029.6%
44
15
8
2
Selling, general and administrative
34
11
+288.5%
10
7
5
3
Pretax income
-141
-59
-1561.0%
-52
-19
-11
-4
Income tax
0
0
0
0
0
0
Net income
-141
-59
-1561.0%
-52
-19
-11
-4
Basic EPS
-3.97
-1.79
-193.4%
-1.71
-0.67
0.54
-0.61
Diluted EPS
-3.97
-1.79
-193.4%
-1.71
-0.67
0.54
-0.61
Weighted average shares, basic
29
33
+469.7%
30
28
25
6
Weighted average shares, diluted
29
33
+469.7%
30
28
25
6
Other measures
Depreciation and amortization
—
0
-47.5%
0
0
—
0
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
LBRX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
New York, NY
SEC filer status
, Emerging growth company
SEC CIK
1691082
Former names
LB PHARMACEUTICALS INC. (until Dec 12, 2018)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.